siRNA-based approaches for castration-resistant prostate cancer therapy targeting the androgen receptor signaling pathway

Yu, Yanling1; Papukashvili, Dimitri2; Ren, Ruimin3; Rcheulishvili, Nino2; Feng, Shunping2; Bai, Wenqi1; Zhang, Huanhu1; Xi, Yanfeng1; Lu, Xiaoqing1; Xing, Nianzeng1

2023-09-01

10.2217/fon-2023-0227

FUTURE ONCOLOGY   影响因子和分区

1479-6694

1744-8301

Androgen deprivation therapy is a common treatment method for metastatic prostate cancer through lowering androgen levels; however, this therapy frequently leads to the development of castration-resistant prostate cancer (CRPC). This is attributed to the activation of the androgen receptor (AR) signaling pathway. Current treatments targeting AR are often ineffective mostly due to AR gene overexpression and mutations, as well as the presence of splice variants that accelerate CRPC progression. Thus there is a critical need for more specific medication to treat CRPC. Small interfering RNAs have shown great potential as a targeted therapy. This review discusses prostate cancer progression and the role of AR signaling in CRPC, and proposes siRNA-based targeted therapy as a promising strategy for CRPC.

ADT androgen receptor CRPC CSPC prostate cancer siRNA

SCI

英语

其他

National Natural Science Foundation of China["82002820","82172659","82072740"]

Oncology

Oncology

WOS:001079325000001

FUTURE MEDICINE LTD

Web of Science

1.Chinese Acad Med Sci, Shanxi Prov Canc Hosp, Shanxi Hosp, Canc Hosp,Shanxi Med Univ, Taiyuan 030001, Peoples R China
2.Southern Univ Sci & Technol, Shenzhen 518000, Peoples R China
3.Shanxi Med Univ, Hosp 3, Shanxi Bethune Hosp, Shanxi Acad Med Sci,Tongji Shanxi Hosp,Dept Urol, Taiyuan 030032, Peoples R China

Yu, Yanling,Papukashvili, Dimitri,Ren, Ruimin,et al. siRNA-based approaches for castration-resistant prostate cancer therapy targeting the androgen receptor signaling pathway[J]. FUTURE ONCOLOGY,2023,19(30).

Yu, Yanling.,Papukashvili, Dimitri.,Ren, Ruimin.,Rcheulishvili, Nino.,Feng, Shunping.,...&Xing, Nianzeng.(2023).siRNA-based approaches for castration-resistant prostate cancer therapy targeting the androgen receptor signaling pathway.FUTURE ONCOLOGY,19(30).

Yu, Yanling,et al."siRNA-based approaches for castration-resistant prostate cancer therapy targeting the androgen receptor signaling pathway".FUTURE ONCOLOGY 19.30(2023).